How a wild bat cost a US tourist more than $20,000
Her doctor father advised her to get rabies vaccinations as a precaution, despite her belief that the bat did not bite her.
Kahn, 33, purchased health insurance online the day after the incident, but the company rejected coverage, citing a 30-day waiting period for services.
She was treated at four different centres, accumulating bills totalling $20,749, which the insurance company refused to pay.
Kahn has since secured a new job, negotiated some bills, set up payment plans, and is appealing the remaining charges.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
29 minutes ago
- Reuters
Former X CEO Yaccarino takes helm at GLP-1 focused telehealth firm eMed
Aug 5 (Reuters) - Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, nearly a month after stepping down as CEO of social media platform X. Yaccarino, an advertising industry veteran, exited Elon Musk's X after two turbulent years during which she tried to revive its reputation among advertisers, who were wary of the platform's content as well as the billionaire's steady stream of controversial posts. Although devoid of any experience in the health sector, she does bring in deep expertise in brand partnerships and digital revenue growth. At NBCUniversal, she modernized the global advertising business over a decade. At X, she helped regain advertiser confidence following turbulence under Musk's ownership. In her first public statement following her appointment, Yaccarino said, "There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before." Gil Luria, an analyst at D.A. Davidson, said Yaccarino brings critical experience in consumer-focused digital platforms. "This new category of apps like Hims and LifeMD are mostly focused on the consumer Ms. Yaccarino's experience is in media, much of that has had to do with creating consumer engagement." Miami, Florida-based eMed, founded in 2020, partners with employers and government payers to manage GLP-1 usage, a class of obesity and diabetes drugs whose cost burden has been a barrier to a wider insurance coverage. The company claims its platform can cut costs of a weight loss program by up to 50%, offering live, on-demand care without appointments. EMed gained traction during the pandemic with at-home COVID-19 tests and later expanded into diagnostics for strep throat and UTIs, though it has since moved away from those offerings. The company currently employs between 51 and 200 people, according to its LinkedIn page.
Reuters
an hour ago
- Reuters
Hims & Hers falls as declining subscriber base weighs on revenue
Aug 5 (Reuters) - Shares of telehealth firm Hims & Hers (HIMS.N), opens new tab fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment as well as the sexual health business. Hims shifted to selling smaller, "personalized" dosages of Novo Nordisk's ( opens new tab popular weight-loss drug, Wegovy, after the U.S. Food and Drug Administration suspended sales of the drug's copies it had allowed during a period of drug shortage. The company recorded $190 million in GLP-1-related revenue, down around $40 million sequentially, as it also lost subscribers on its commercially available doses of Wegovy. Novo Nordisk ( opens new tab in June terminated its partnership with Hims over the company's marketing tactics and continued sales of Wegovy copies even after FDA's ban on such sales. Leerink Partners analysts flagged the GLP-1 revenue dip as expected. However, the market reaction was negative after the results, as investor expectations were elevated, due to a surge in shares this year. Hims' stock has more than doubled so far this year, while Denmark-listed shares of Novo have fallen over 50%. The brokerage called the softness in Hims' core business, which includes treatments for conditions related to sexual health, a negative surprise. Hims & Hers reported a decline in its subscribers for its sexual health business, which sells generic drugs for erectile dysfunction. Canaccord Genuity echoed a near-term caution for the company, but remained constructive on the longer-term growth potential, citing strong year-over-year gains in newer specialties such as dermatology, weight management, and daily-use sexual health solutions. Despite the stock's sharp post-earnings pullback, the brokerage called the move a potential buying opportunity. Hims shares are priced at 95.85 times the company's estimated earnings for the next 12 months, a common benchmark for valuing stocks.
Daily Mail
2 hours ago
- Daily Mail
FDA issues highest recall alert for 33,000lbs of snack food distributed nationwide... 'reasonable probability of death'
An urgent recall has been issued for a popular snack distributed nationwide for being contaminated with a diarrhea-causing bacteria. Texas-based Navarro Pecan Holdings issued a voluntary recall of 32,670 pounds of pecan products on July 10 due to concerns about potential Salmonella contamination. The products were distributed to commercial and retail distributors in five states; Texas, Minnesota, Oklahoma, Arkansas and New Jersey. They were also distributed internationally to Italy, the Netherlands and UAE, the FDA said. The government agency has updated the recall as Class I, as the nuts have the potential to be contaminated with the bacteria salmonella, which hospitalizes 26,000 Americans every year. A Class I recall is a 'situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death'. The FDA says salmonella can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy people infected with the bacteria often experience fever, diarrhea, nausea, vomiting and abdominal pain. No other products produced by Navarro Pecan Holdings have been impacted and as of yet, there have been no reported illnesses. Founded in 1977, Navarro Pecan Holdings prides itself on being one of the largest pecan shellers in the world. It is not clear how the Salmonella contamination was discovered. Salmonella is an infection contracted from eating foods contaminated with animal feces. It typically causes diarrhea, fever, and stomach cramps that begin six hours to six days after initial infection. Most people recover within days, though the illness is responsible for more than 26,000 hospitalizations and 400 deaths a year. The CDC estimates that most Salmonella infections are linked to chicken, fruits, pork, and seeded vegetables (such as tomatoes). But any food can become contaminated, even processed foods, such as flour. Nuts can become contaminated with Salmonella during various stages of production, including pre-harvest, harvest, processing, and storage. Contamination can occur from soil, contaminated harvesting equipment, and inadequate storage conditions. Moisture during the storage period can also contribute to the spread of Salmonella. The recalled products from Navarro Pecan Holdings include small and medium pecan pieces and mammoth pecan halves. Distributors and consumers who purchased the pecans should return it to the retailer for a full refund. The FDA has advised anyone who falls ill after eating the product to contact local health authorities. Most people sickened with salmonella suffer from a four to six-day illness that causes stomach cramps, diarrhea and abdominal pain. But officials warn children under five years and adults over 65 years old are more at risk from the bacteria because they have a weaker immune system. In serious cases, the bacteria can cause bloody stools and prolonged vomiting. People can die from salmonella via dehydration or if the bacteria enters the bloodstream, which can lead to sepsis, a life-threatening reaction.
